2019
ATIM-47. NIVOLUMAB VS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: EXPLORATORY ANALYSIS OF MGMT METHYLATION STATUS AND BASELINE CORTICOSTEROID USE
Weller M, Reardon D, Brandes A, Sampson J, Mulholland P, Wick A, Baehring J, Ahluwalia M, Roth P, Bähr O, Phuphanich S, Sepulveda J, de Souza P, Sahebjam S, Potter V, Tatsuoka K, Taitt C, Zwirtes R, Omuro A, Lim M. ATIM-47. NIVOLUMAB VS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: EXPLORATORY ANALYSIS OF MGMT METHYLATION STATUS AND BASELINE CORTICOSTEROID USE. Neuro-Oncology 2019, 21: vi12-vi12. PMCID: PMC6847600, DOI: 10.1093/neuonc/noz175.045.Peer-Reviewed Original ResearchMedian overall survivalBaseline corticosteroid useCorticosteroid useBaseline corticosteroidsMGMT methylation statusRecurrent glioblastomaUnmethylated tumorsMultivariable Cox proportional hazards model analysisCox proportional hazards model analysisLonger median overall survivalProportional hazards model analysisBevacizumab-treated patientsLimited survival benefitNivolumab-treated patientsSubgroup of patientsExploratory subgroup analysisHazards model analysisMethyltransferase promoter methylation statusDNA methyltransferase promoter methylation statusMethylation statusMGMT promoter statusTemozolomide chemoradiotherapyFirst recurrencePrimary endpointOverall survival
2014
AT-23A PHASE II STUDY OF LAPATINIB AND DOSE-DENSE TEMOZOLOMIDE (TMZ) FOR ADULTS WITH RECURRENT EPENDYMOMA: A CERN CLINICAL TRIAL
Gilbert M, Yuan Y, Wani K, Wu J, Omuro A, Lieberman F, Robins H, Gerstner E, Wu J, Wen P, Mikkelsen T, Armstrong T, Aldape K. AT-23A PHASE II STUDY OF LAPATINIB AND DOSE-DENSE TEMOZOLOMIDE (TMZ) FOR ADULTS WITH RECURRENT EPENDYMOMA: A CERN CLINICAL TRIAL. Neuro-Oncology 2014, 16: v13-v13. PMCID: PMC4217801, DOI: 10.1093/neuonc/nou237.23.Peer-Reviewed Original ResearchDose-dense temozolomideClinical trialsPredictive markerFirst prospective clinical trialPhase II studyPrimary CNS tumorsProspective clinical trialsPossible predictive markerPotential predictive markerPatient reported outcomesSubsequent clinical trialsMGMT promoter statusMedian KPSMedian progressionPrimary endpointRecurrent diseaseII studyOverall survivalSymptom burdenMedian ageInitial treatmentCNS tumorsExtensive resectionStandard treatmentPRO collection